Ultragenyx Pharmaceu (RARE) 66.27 $RARE
Ultragenyx to Present at Baird 2016 Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Baird 2016 Global Healthcare Conference on Thursday, September 8 at 10:15 am ET in New York, NY.
RARE: 66.27 (+0.35)
Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting
GlobeNewswire - Tue Aug 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.
RARE: 66.27 (+0.35)
How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 49.33 (-0.01), ALDR: 32.54 (-0.43), SAGE: 36.96 (-0.21), RARE: 66.27 (+0.35)
Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 09, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
RARE: 66.27 (+0.35)
Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 08, 3:08PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2016.
RARE: 66.27 (+0.35)
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 237.76 (+3.22), ENDP: 20.23 (-0.47), JNJ: 119.08 (-0.26), RARE: 66.27 (+0.35), KITE: 58.87 (+1.25), HZNP: 18.62 (-0.18), NVS: 78.27 (-0.50)
Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, August 8, 2016 at 5pm ET to discuss second quarter 2016 financial results and provide a corporate update.
RARE: 66.27 (+0.35)
Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH)
GlobeNewswire - Thu Jul 28, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of KRN23 for the treatment of adults with X-linked hypophosphatemia (XLH). Data from the study are expected in 2017.
RARE: 66.27 (+0.35)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 237.76 (+3.22), RARE: 66.27 (+0.35)
Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Ultragenyx to license and develop one or more product candidates from Takeda
RARE: 66.27 (+0.35)
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:45AM CDT
Ultragenyx Pharmaceutical Inc. (RARE) was a big mover last session, as the company saw its shares rise over 6% on the day.
RARE: 66.27 (+0.35), ANIP: 61.42 (+1.68)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.68 (-0.09), RARE: 66.27 (+0.35), ICPT: 146.82 (-1.49), JUNO: 29.29 (-0.29)
Ultragenyx reports 1Q loss
Automated Insights - Mon May 09, 3:25PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $52.8 million in its first quarter.
RARE: 66.27 (+0.35)
Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon May 09, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2016.
RARE: 66.27 (+0.35)
Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Fri May 06, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 11, 2016 at 1:00pm PT in Las Vegas, NV.
RARE: 66.27 (+0.35)
Ultragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 9, 2016 at 5pm ET to discuss first quarter 2016 financial results and provide a corporate update.
RARE: 66.27 (+0.35)
Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim data from the Phase 2 study of KRN23 for the treatment of tumor-induced osteomalacia (TIO). Initial data from the first eight patients in the study, including one patient with epidermal nevus syndrome (ENS), demonstrated that KRN23 improved serum phosphorus levels and other bone metabolism measures. The study has been expanded to enroll approximately 15 patients, and enrollment is ongoing.
RARE: 66.27 (+0.35)
Ultragenyx and Saint Louis University's Center for World Health and Medicine Announce Research Collaboration to Advance Muscular Dystrophy Treatment
GlobeNewswire - Wed Mar 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University's (SLU) Center for World Health and Medicine, today announced that they have entered into three-year sponsored research and option agreements to collaborate on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
RARE: 66.27 (+0.35)
Ultragenyx to Present at the Leerink Partners Annual Healthcare Conference
GlobeNewswire - Tue Feb 09, 7:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the LEERINK Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
RARE: 66.27 (+0.35)
Ultragenyx to Present at Baird 2016 Global Healthcare Conference
GlobeNewswire - Thu Sep 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Baird 2016 Global Healthcare Conference on Thursday, September 8 at 10:15 am ET in New York, NY.
RARE: 66.27 (+0.35)
Ultragenyx Announces KRN23 Data Presentations at ASBMR 2016 Annual Meeting
GlobeNewswire - Tue Aug 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting KRN23 for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO) at the American Society for Bone and Mineral Research (ASBMR) 2016 Annual Meeting taking place September 16-19 in Atlanta, Georgia.
RARE: 66.27 (+0.35)
How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma
PR Newswire - Wed Aug 10, 7:20AM CDT
Despite regulatory concerns, M&A activities are expected to continue pushing some Biotech stocks to new highs. The industry belongs in the Healthcare sector which was up by 0.6% on Tuesday, August 09, 2016. Stock-Callers.com takes a look at today's featured companies and see how they fared at the close: bluebird bio Inc. (NASDAQ: BLUE), Sage Therapeutics Inc. (NASDAQ: SAGE), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Alder Biopharmaceuticals Inc. (NASDAQ: ALDR). Register now and get full and free access to our downloadable research reports on these stocks at:
BLUE: 49.33 (-0.01), ALDR: 32.54 (-0.43), SAGE: 36.96 (-0.21), RARE: 66.27 (+0.35)
Ultragenyx to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Aug 09, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
RARE: 66.27 (+0.35)
Ultragenyx Reports Second Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 08, 3:08PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2016.
RARE: 66.27 (+0.35)
5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 8:24AM CDT
As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared.
AGN: 237.76 (+3.22), ENDP: 20.23 (-0.47), JNJ: 119.08 (-0.26), RARE: 66.27 (+0.35), KITE: 58.87 (+1.25), HZNP: 18.62 (-0.18), NVS: 78.27 (-0.50)
Ultragenyx to Host Conference Call for Second Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon Aug 01, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, August 8, 2016 at 5pm ET to discuss second quarter 2016 financial results and provide a corporate update.
RARE: 66.27 (+0.35)
Ultragenyx Announces Completion of Enrollment in Phase 3 Study of KRN23 in Adults with X-Linked Hypophosphatemia (XLH)
GlobeNewswire - Thu Jul 28, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has completed patient enrollment in the Phase 3 study of KRN23 for the treatment of adults with X-linked hypophosphatemia (XLH). Data from the study are expected in 2017.
RARE: 66.27 (+0.35)
Ultragenyx Appoints Karah Parschauer as Executive Vice President, General Counsel
GlobeNewswire - Mon Jun 20, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it has appointed Karah Parschauer as Executive Vice President, General Counsel. In this newly created role, she will be responsible for leading the company's legal, compliance, and corporate governance functions. She will report to Emil D. Kakkis, M.D., Ph.D., Ultragenyx's Chief Executive Officer, and will serve on the Executive Leadership Team.
AGN: 237.76 (+3.22), RARE: 66.27 (+0.35)
Ultragenyx and Takeda enter into a Collaboration to Develop and Commercialize Therapies for Rare Genetic Diseases
GlobeNewswire - Tue Jun 07, 6:00AM CDT
Ultragenyx to license and develop one or more product candidates from Takeda
RARE: 66.27 (+0.35)
Ultragenyx Pharmaceutical (RARE) Jumps: Stock Up 6.6%
Zacks Equity Research - Zacks Investment Research - Wed Jun 01, 7:45AM CDT
Ultragenyx Pharmaceutical Inc. (RARE) was a big mover last session, as the company saw its shares rise over 6% on the day.
RARE: 66.27 (+0.35), ANIP: 61.42 (+1.68)
Why These Biotech Stocks Have Been on Investors' Radar? - Juno Therapeutics, Immunomedics, Ultragenyx Pharma, and Intercept Pharma
PR Newswire - Wed May 25, 7:10AM CDT
The Biotech arena may not be in its best shape right now, but this does not mean investors are sidelining stocks in this space. Here are today's ActiveWallSt.com highlights: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), and Intercept Pharmaceuticals Inc. (NASDAQ: ICPT). Get the free access these stocks' technical alerts by clicking below:
IMMU: 2.68 (-0.09), RARE: 66.27 (+0.35), ICPT: 146.82 (-1.49), JUNO: 29.29 (-0.29)
Ultragenyx reports 1Q loss
Automated Insights - Mon May 09, 3:25PM CDT
NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $52.8 million in its first quarter.
RARE: 66.27 (+0.35)
Ultragenyx Reports First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Mon May 09, 3:05PM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2016.
RARE: 66.27 (+0.35)
Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference
GlobeNewswire - Fri May 06, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 11, 2016 at 1:00pm PT in Las Vegas, NV.
RARE: 66.27 (+0.35)
Ultragenyx to Host Conference Call for First Quarter 2016 Financial Results and Corporate Update
GlobeNewswire - Fri Apr 29, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 9, 2016 at 5pm ET to discuss first quarter 2016 financial results and provide a corporate update.
RARE: 66.27 (+0.35)
Ultragenyx Reports Positive Interim Data from Phase 2 Study of KRN23 for the Treatment of Tumor-Induced Osteomalacia
GlobeNewswire - Thu Apr 21, 7:31AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim data from the Phase 2 study of KRN23 for the treatment of tumor-induced osteomalacia (TIO). Initial data from the first eight patients in the study, including one patient with epidermal nevus syndrome (ENS), demonstrated that KRN23 improved serum phosphorus levels and other bone metabolism measures. The study has been expanded to enroll approximately 15 patients, and enrollment is ongoing.
RARE: 66.27 (+0.35)
Ultragenyx and Saint Louis University's Center for World Health and Medicine Announce Research Collaboration to Advance Muscular Dystrophy Treatment
GlobeNewswire - Wed Mar 23, 7:30AM CDT
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Saint Louis University's (SLU) Center for World Health and Medicine, today announced that they have entered into three-year sponsored research and option agreements to collaborate on the development of small molecule therapeutics for the potential treatment of Facioscapulohumeral Muscular Dystrophy (FSHD).
RARE: 66.27 (+0.35)
Ultragenyx to Present at the Leerink Partners Annual Healthcare Conference
GlobeNewswire - Tue Feb 09, 7:00AM CST
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will be presenting at the LEERINK Partners 5 Annual Global Healthcare Conference on Wednesday, February 10, 2016 at 8:00am ET at the Waldorf Astoria in New York, NY.
RARE: 66.27 (+0.35)
